Sadbhav Infrastructure Projects Says Q3 Toll Revenue From SPVs Up 6.2 Pct [Reuters]
Spero Therapeutics, Inc. (SPRO)
Last spero therapeutics, inc. earnings: 3/16 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.sperotherapeutics.com/overview
Company Research
Source: Reuters
Spero Therapeutics Inc (SPRO.OQ) Key Developments | Reuters.com Jan 7 (Reuters) - Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES POSITIVE FEEDBACK FROM FDA PRE-PHASE 3 MEETING FOR ORAL SPR994 AND SUBMISSION OF IND FOR SPR994 IN CUTI.SPERO THERAPEUTICS INC - FDA MEETING SUPPORTS SINGLE PIVOTAL PHASE 3 CLINICAL TRIAL OF SPR994 IN CUTI.SPERO THERAPEUTICS INC - SPR994 IND SUBMITTED AND ADAPT-PO PHASE 3 STARTUP ACTIVITIES UNDERWAY.SPERO THERAPEUTICS INC - ANTICIPATES OPENING TRIAL SITES TO SUPPORT STUDY ENROLLMENT IN Q1 OF 2019. Full Article Nov 8 (Reuters) - Spero Therapeutics Inc ::SPERO THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PIPELINE OVERVIEW.Q3 LOSS PER SHARE $0.60.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, COMPANY'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $131.2 MILLION.CONTINUES TO EXPECT THAT ITS RESEARCH AND DEVELOPMENT EXPENSES WILL INCREASE THROUGH REMAINDER OF 2018.EXPECTS GENERAL AND
Show less
Read more
Impact Snapshot
Event Time:
SPRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRO alerts
High impacting Spero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SPRO
News
- Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
- Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market? [Yahoo! Finance]Yahoo! Finance
SPRO
Earnings
- 3/13/24 - Beat
SPRO
Sec Filings
- 4/16/24 - Form ARS
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- SPRO's page on the SEC website